A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)

Obesity

Volumn 21, Issue 5, 2013, Pages 935-943

  Apovian, Caroline M ^a   Aronne, Louis ^b   Rubino, Domenica ^c   Still, Christopher ^d   Wyatt, Holly ^e   Burns, Colleen ^f   Kim, Dennis ^f,g   Dunayevich, Eduardo ^f,h  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Washington Center for Weight Management and Research   (United States)

^d GEISINGER HEALTH SYSTEM   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f Orexigen Therapeutics   (United States)

^g One Cambridge Center   (United States)

^h AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRONCHITIS; CARDIOMETABOLIC RISK; CLINICAL STUDY; CONSTIPATION; CONTRATIVE OBESITY RESEARCH II; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEEDING BEHAVIOR; FEMALE; HEART RATE; HUMAN; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBESITY; PHASE 3 CLINICAL TRIAL; PULSE RATE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SINUSITIS; SLEEP DISORDER; SUICIDAL BEHAVIOR; SUSTAINED DRUG RELEASE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WAIST CIRCUMFERENCE; WEIGHT CHANGE; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; ANTI-OBESITY AGENTS; BUPROPION; CARDIOVASCULAR DISEASES; DELAYED-ACTION PREPARATIONS; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEEDING BEHAVIOR; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; NAUSEA; OBESITY; OVERWEIGHT; QUALITY OF LIFE; RISK FACTORS; WEIGHT LOSS;

EID: 84879324574     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20309     Document Type: Article

References (26)

1. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM,. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 2004; 291: 2847-28s50.
2. Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005; 352: 1138-1145.
3. NHLBI/NIDDK. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Institutes of Health: Bethesda, 1998.
4. Grodstein F, Levine R, Troy L, Spencer T, Colditz GA, Stampfer MJ,. Three-year follow-up of participants in a commercial weight loss program. Can you keep it off? Arch Intern Med 1996; 156: 1302-1306.
5. Riddle M,. Combining sulfonylureas and other oral agents. Am J Med 2000; 108 Suppl 6a: 15S-22S.
6. Gradman AH, Acevedo C,. Evolving strategies for the use of combination therapy in hypertension. Curr Hypertens Rep 2002; 4: 343-349.
7. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW,. Central nervous system control of food intake and body weight. Nature 2006; 443: 289-295.
8. Sinnayah P, Wallingford NM, Evans AE, Cowley MA,. Bupropion and naltrexone interact synergistically to decrease food intake in mice. In: North American Association for the Study of Obesity Annual Scientific Meeting, New Orleans, LA 2007.
9. Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity 2009; 17: 30-39.
10. Prescribing Information: Vivitrol (naltrexone for extended-release injectable suspension). 2010.
11. Prescribing Information: Zyban (bupropion hydrochloride) sustained-release tablets. 2012. pp 1-34.
12. Greenway FL, Dunayevich E, Tollefson G, et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 2009; 94: 4898-4906.
13. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595-605.
14. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD Trial. Obesity (Silver Spring) 2011; 19: 110-120.
15. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Int Bioethique 2004; 15: 124-129.
16. Crosby RD, Kolotkin RL, Williams GR,. An integrated method to determine meaningful changes in health-related quality of life. J Clin Epidemiol 2004; 57: 1153-1160.
17. Wilcox CS, Oskooilar N, Erickson JS, et al. An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addict Behav 2010; 35: 229-234.
18. Rush AJ, Carmody TP, Reimitz PE,. The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. International Journal of Methods in Psychiatric Research 2000; 9: 45-59.
19. SDI. Occurrences of bupropion prescriptions by BMI, Jan-Dec. 2009.
20. Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 2008; 51: 55-61.
21. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005; 46: 156-161.
22. Volkow ND, Wise RA,. How can drug addiction help us understand obesity? Nat Neurosci 2005; 8: 555-560.
23. Pelchat ML,. Food cravings in young and elderly adults. Appetite 1997; 28: 103-113.
24. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532-546.
25. Rucker D, Padwal R, Li SK, Curioni C, Lau DC,. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194-1199.
26. Health I,. The National Disease and Therapeutic Index. Plymouth, PA, 1998-2003.